Penile carcinoma
diseaseOn this page
Also known as cancer of peniscancer of the peniscancer peniscarcinoma of peniscarcinoma of the penispenile cancerpenile cancer, adultpenis carcinoma
Summary
Penile carcinoma (MONDO:0006360) is a cancer and 71 clinical trials. Top therapeutic interventions include cabozantinib, avelumab, and dostarlimab. A subtype of penile cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 71
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | penile carcinoma |
| Mondo ID | MONDO:0006360 |
| EFO | EFO:1000465 |
| DOID | DOID:3449 |
| NCIT | C9061 |
| SNOMED CT | 372106005 |
| UMLS | C0853105 |
| MedGen | 208877 |
| GARD | 0024383 |
| Anatomy (UBERON) | UBERON:0000989 |
| Is cancer (heuristic) | yes |
Also known as: cancer of penis · cancer of the penis · cancer penis · carcinoma of penis · carcinoma of the penis · penile cancer · penile cancer, adult · penile carcinoma · penis carcinoma
Disease family
This is a subtype of penile cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › male reproductive organ cancer › penile cancer › penile carcinoma
Related subtypes (3): penile sarcoma, glans penis cancer, penile urethral cancer
Subtypes (3): Paget disease of the penis, penis basal cell carcinoma, squamous cell carcinoma of penis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dostarlimab, Niraparib, Pembrolizumab.
Clinical trials & evidence
Clinical trials
Clinical trials: 71.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 32 |
| Not specified | 24 |
| PHASE1 | 11 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06465914 | PHASE3 | ACTIVE_NOT_RECRUITING | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males |
| NCT02721732 | PHASE2 | ACTIVE_NOT_RECRUITING | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic |
| NCT02817958 | PHASE2 | ACTIVE_NOT_RECRUITING | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis |
| NCT03333616 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
| NCT03391479 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy |
| NCT03866382 | PHASE2 | RECRUITING | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
| NCT04708470 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
| NCT05526989 | PHASE2 | RECRUITING | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma |
| NCT05639972 | PHASE1/PHASE2 | RECRUITING | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers |
| NCT05686226 | PHASE2 | RECRUITING | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers |
| NCT05969860 | PHASE2 | RECRUITING | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
| NCT06104618 | PHASE2 | RECRUITING | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis |
| NCT06353906 | PHASE2 | RECRUITING | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer |
| NCT06415318 | PHASE2 | RECRUITING | TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer |
| NCT06683846 | PHASE2 | RECRUITING | Ivonescimab in the Treatment of Multiple Advanced Tumors |
| NCT06684327 | PHASE2 | RECRUITING | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors |
| NCT07101822 | PHASE2 | NOT_YET_RECRUITING | A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER |
| NCT07384416 | PHASE2 | RECRUITING | QL1706 Plus Lenvatinib in Previously Treated Penile Cancer |
| NCT07497919 | PHASE2 | NOT_YET_RECRUITING | A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer |
| NCT07518979 | PHASE2 | NOT_YET_RECRUITING | EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer |
| NCT00002506 | PHASE2 | COMPLETED | Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer |
| NCT00058448 | PHASE2 | TERMINATED | S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) |
| NCT00066391 | PHASE2 | COMPLETED | Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer |
| NCT00512096 | PHASE2 | COMPLETED | Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis |
| NCT01209325 | PHASE2 | COMPLETED | Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males |
| NCT01585428 | PHASE2 | COMPLETED | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers |
| NCT02280811 | PHASE1/PHASE2 | COMPLETED | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers |
| NCT03427411 | PHASE2 | COMPLETED | M7824 in Subjects With HPV Associated Malignancies |
| NCT03439085 | PHASE2 | TERMINATED | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers |
| NCT03686332 | PHASE2 | COMPLETED | PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study |
| NCT03774901 | PHASE2 | UNKNOWN | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma |
| NCT04224740 | PHASE2 | COMPLETED | Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer |
| NCT04231981 | PHASE2 | COMPLETED | Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) |
| NCT04357873 | PHASE2 | COMPLETED | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations |
| NCT04475016 | PHASE2 | COMPLETED | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer |
| NCT04718584 | PHASE2 | UNKNOWN | the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT04491942 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer |
| NCT05952947 | PHASE1 | RECRUITING | HRYZ-T101 Injection for HPV18 Positive Solid Tumor |
| NCT05999396 | PHASE1 | RECRUITING | FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 4 |
| AVELUMAB | 4 | 1 |
| DOSTARLIMAB | 4 | 1 |
| ENFORTUMAB VEDOTIN | 4 | 1 |
| ISOTRETINOIN | 4 | 1 |
| RETIFANLIMAB | 4 | 1 |
| BECOTATUG VEDOTIN | 3 | 2 |
| BINTRAFUSP ALFA | 3 | 2 |
| PUCOTENLIMAB | 3 | 2 |
| ENTINOSTAT | 3 | 1 |
| NIMOTUZUMAB | 3 | 1 |
| FAPI-46 GA-68 | 2 | 1 |
| ELIMUSERTIB | 1 | 1 |